(Total Views: 552)
Posted On: 10/30/2025 4:56:56 PM
Post# of 158249
Simple Question: Haven't many/most small biotechs been bought out (or "partnered up"
with a whole lot less evidence of efficacy, potential, and proven safety profile than Cytodyn?
If the science and MOA behind Leronlimab is solid - and from what the academic papers and those on our SAB vigorously and thoroughly confirm - then year after year, why do sit in the share price cellar?
The BP scientists aren't stupid, they know what our molecule can do and how much incredible $$$ potential it has, so what gives?
The only thing that makes sense to me is BP hoping to come up with their own miracle molecule so they don't need ours . . . and if they can't develop their own version of LL, if they string us along long enough until we run out of cash? Then all the better: they either get LL on the cheap or just bury it away.
At this point, with so much promise and potential, nothing else makes sense.
with a whole lot less evidence of efficacy, potential, and proven safety profile than Cytodyn? If the science and MOA behind Leronlimab is solid - and from what the academic papers and those on our SAB vigorously and thoroughly confirm - then year after year, why do sit in the share price cellar?
The BP scientists aren't stupid, they know what our molecule can do and how much incredible $$$ potential it has, so what gives?
The only thing that makes sense to me is BP hoping to come up with their own miracle molecule so they don't need ours . . . and if they can't develop their own version of LL, if they string us along long enough until we run out of cash? Then all the better: they either get LL on the cheap or just bury it away.
At this point, with so much promise and potential, nothing else makes sense.
(8)
(1)
